



Title	Liver Failure From Ultra-Short Bowel Syndrome on the Intestinal Transplant Waiting List: A Retrospective Study
Author(s)	Noguchi, Y.; Ueno, T.; Matsuura, R. et al.
Citation	Transplantation Proceedings. 2017, 49(1), p. 135-138
Version Type	AM
URL	https://hdl.handle.net/11094/99833
rights	© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
Note	

The University of Osaka Institutional Knowledge Archive : OUKA

<https://ir.library.osaka-u.ac.jp/>

The University of Osaka

		Dead	Alive	P	
at registration	Pathology (F)	1.50 (1.25-1.75)	1.00 (0.500-1.50)	0.76	
	AST (U/L)	59.5 (56.8-62.3)	30.0 (22.0-35.0)	0.20	
	T-Bil (mg/dL)	1.45 (0.875-2.03)	0.800 (0.500-0.850)	0.80	
	Alb (g/dL)	3.20 (2.95-3.45)	3.80 (3.75-4.00)	0.24	
	PT (%)	57.5 (49.8-65.3)	69.0 (62.5-79.5)	0.80	
	Ch-E (U/L)	180 (143-216)	263 (249-369)	0.40	
	Citrulline (μmol/L)	16.2 (13.7-18.6)	28.9 (20.5-29.1)	0.40	
	Pre-Alb (mg/dL)	17.8 (16.2-19.3)	17.1 (15.0-19.8)	1.00	
	at the latest	Pathology (F)	2.50 (2.25-2.75)	1.50 (1.25-1.75)	0.41
		AST (U/L)	46.0 (41.5-50.5)	35.0 (32.0-40.5)	0.40
T-Bil (mg/dL)		1.85 (1.63-2.08)	0.50 (0.350-1.05)	0.40	
Alb (g/dL)		2.85 (2.73-2.98)	3.50 (3.45-3.90)	0.20	
PT (%)		41.0 (41.0-41.0)	75.0 (72.5-78.5)	0.14	
Ch-E (U/L)		192 (155-228)	202 (196-322)	0.80	
Citrulline (μmol/L)		2.70 (1.35-4.05)	16.5 (14.0-22.4)	0.20	
Pre-Alb (mg/dL)		10.0 (9.85-10.2)	22.5 (18.2-23.3)	0.20	

		Dead	Alive	P	
at registration	Pathology (F)	1.50 (1.25-1.75)	1.00 (0.50-1.50)	0.76	
	AST (U/L)	59.5 (56.8-62.3)	30.0 (22.0-35.0)	0.20	
	T-Bil (mg/dL)	1.45 (0.88-2.03)	0.80 (0.50-0.85)	0.80	
	Alb (g/dL)	3.20 (2.95-3.45)	3.80 (3.75-4.00)	0.24	
	PT (%)	57.5 (49.8-65.3)	69.0 (62.5-79.5)	0.80	
	Ch-E (U/L)	180 (143-216)	263 (249-369)	0.40	
	Citrulline (μmol/L)	16.2 (13.7-18.6)	28.9 (20.5-29.1)	0.40	
	Pre-Alb (mg/dL)	17.8 (16.2-19.3)	17.1 (15.0-19.8)	1.00	
	at the latest	Pathology (F)	2.50 (2.25-2.75)	1.50 (1.25-1.75)	0.41
		AST (U/L)	46.0 (41.5-50.5)	35.0 (32.0-40.5)	0.40
T-Bil (mg/dL)		1.85 (1.63-2.08)	0.50 (0.35-1.05)	0.40	
Alb (g/dL)		2.85 (2.73-2.98)	3.50 (3.45-3.90)	0.20	
PT (%)		41.0 (41.0-41.0)	75.0 (72.5-78.5)	0.14	
Ch-E (U/L)		192 (155-228)	202 (196-322)	0.80	
Citrulline (μmol/L)		2.70 (1.35-4.05)	16.5 (14.0-22.4)	0.20	
Pre-Alb (mg/dL)		10.0 (9.85-10.2)	22.5 (18.2-23.3)	0.20	

		Dead	Alive	P	
at registration	Liver fibrosis (F)	1.50 (1.25-1.75)	1.00 (0.50-1.50)	0.76	
	T-Bil (mg/dL)	1.45 (0.88-2.03)	0.80 (0.50-0.85)	0.80	
	Alb (g/dL)	3.20 (2.95-3.45)	3.80 (3.75-4.00)	0.24	
	PT (%)	57.5 (49.8-65.3)	69.0 (62.5-79.5)	0.80	
	Citrulline (μmol/L)	16.2 (13.7-18.6)	28.9 (20.5-29.1)	0.40	
	Pre-Alb (mg/dL)	17.8 (16.2-19.3)	17.1 (15.0-19.8)	1.00	
	at the latest	Liver fibrosis (F)	2.50 (2.25-2.75)	1.50 (1.25-1.75)	0.41
		T-Bil (mg/dL)	1.85 (1.63-2.08)	0.50 (0.35-1.05)	0.40
Alb (g/dL)		2.85 (2.73-2.98)	3.50 (3.45-3.90)	0.20	
PT (%)		41.0 (41.0-41.0)	75.0 (72.5-78.5)	0.14	
Citrulline (μmol/L)		2.70 (1.35-4.05)	16.5 (14.0-22.4)	0.20	
Pre-Alb (mg/dL)	10.0 (9.85-10.2)	22.5 (18.2-23.3)	0.20		



median (range)

Case	Age at registration(year)	Sex	Primary disease	Residual intestinal length (cm)	Waiting time (month)	Outcome
1	31	M	Acute cellular rejection after ITx	15	31	Dead
2	27	F	Total colon aganglionosis	80	36	Alive
3	24	F	SMV embolization	0	14	Dead
4	13	M	CIIPS	70	8	Alive
5	6	F	CIIPS	50	9	Alive


Case	Age at registration (year)	Sex	Primary disease	Residual intestinal length (cm)	Waiting time (month)	Outcome
1	31	M	Acute cellular rejection after ITx	15	31	Dead
2	27	F	Total colon aganglionosis	80	36	Alive
3	24	F	SMV embolization	0	14	Dead
4	13	M	CIIPS	70	8	Alive
5	6	F	CIIPS	50	9	Alive

Case	Age at registration (year)	Sex	Primary disease	Residual intestinal length (cm)	Waiting time (month)	Outcome
1	31	M	Acute cellular rejection after ITx	15	31	Dead
2	27	F	Total colon aganglionosis	80	36	Alive
3	24	F	SMV embolization	0	14	Dead
4	13	M	CIIPS	70	8	Alive
5	6	F	CIIPS	50	9	Alive

CIIPS: chronic idiopathic intestinal pseudo-obstruction syndrome



F: liver fibrosis status evaluated with the new Inuyama classification system. acute cellular rejection, ACR; acute renal failure, ARF; continuous hemodiafiltration, CHDF; intestinal transplantation, ITx; living donor liver transplantation, LDLT; liver failure, LF.



F: liver fibrosis status evaluated with the new Inuyama classification system. acute cellular rejection, ACR; acute renal failure, ARF; continuous hemodiafiltration, CHDF; intestinal transplantation, ITx; living donor liver transplantation, LDLT; liver failure, LF.